AVGN Avigen (MM)

Webcast Scheduled for 9:30 a.m. (PDT) on Monday, September 11, 2006 ALAMEDA, Calif., Sept. 5 /PRNewswire-FirstCall/ -- Avigen, Inc. (NASDAQ:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions, announced today that President and Chief Executive Officer Kenneth Chahine, Ph.D., J.D., will present at the Think Equity Partners 4th Annual Growth Conference: -- Monday, September 11, 2006 -- from 9:30 to 10:00 a.m. PDT in San Francisco at the Ritz Carlton Hotel. Avigen will conduct a live webcast of the presentation. To access the webcast over the Internet, please go to http://www.avigen.com/ . Rebroadcast of the presentation will be available shortly after the conclusion of the session and can be accessed over the internet at http://www.avigen.com/ . About Avigen Avigen is a biopharmaceutical company focused on unique small molecule therapeutics and biologics to treat serious neurological disorders, including neuropathic pain and neuromuscular spasm and spasticity. Avigen's strategy is to complete the requirements of clinical development for each of the candidates in its product pipeline, and continue to look for opportunities to expand its pipeline through a combination of internal research, acquisitions, and in-licensing, with the goal of becoming a fully integrated commercial biopharmaceutical company committed to its small molecule and biologics neurology products. The company is currently developing AV650 for spasticity and neuromuscular spasm and two candidates for neuropathic pain, AV411 and AV333. Additionally, the company is advancing toward clinical trials a novel therapy for the treatment of multiple bleeding disorders, including hemophilia A and B, AV513. For more information about Avigen, consult the company's website at http://www.avigen.com/ . Statement under the Private Securities Litigation Reform Act This advisory may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements in this advisory include statements addressing the following subjects: Avigen, Inc.'s (the "Company") belief that it will be able to expand its pipeline through internal research, acquisitions, and/or in- licensing, and that it will be able to develop, commercialize or obtain value from its current drug candidates for any indication. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the fact that development of small molecule therapeutics and other therapeutic discovery and development is a time- and resource-intensive process, which may result in the expenditure of a significant amount of time and resources with no marketable product resulting from the effort. Other risks and uncertainties relating to Avigen are detailed in reports filed by Avigen with the Securities and Exchange Commission, including Avigen's quarterly report on Form 10-Q for the period ended June 30, 2006, under the caption "Risk Factors" in Item 1 of Part 1A of that report, which was filed with the SEC on August 4, 2006. DATASOURCE: Avigen, Inc. CONTACT: Michael Coffee, Chief Business Officer, Avigen, Inc., +1-510-748-7372, or Web site: http://www.avigen.com/

Copyright